2012 Fiscal Year Final Research Report
Application of in-house monoclonal antibody resources to a fully retargeted oncolytic herpes simplex virus platform
| Project/Area Number |
23800058
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
UCHIDA Hiroaki 東京薬科大学, 生命科学部, 准教授 (20401250)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | 遺伝子治療 / 癌 / 腫瘍溶解ウイルス療法 / 単純ヘルペスウイルス / 抗体医薬 |
|---|
| Research Abstract |
We have reported a fully retargeted herpes simplex virus (HSV) platform that incorporates single-chain antibodies to mediate virus entry exclusively via tumor-associated antigens. For further development of this system, we successfully took advantage of our own collection of monoclonal antibodies directed against human cancers. Our results indicate the adaptability of our system to different targeting ligands, leading to a new generation of broadly applicable and effective oncolytic HSV vectors.
|
-
[Journal Article] Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus2013
Author(s)
Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CH, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB, Glorioso JC
-
Journal Title
Mol Ther
Volume: 21(3)
Pages: 561-9
-
-
[Journal Article] Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV
Author(s)
Wang PY, Currier MA, Hansford L, Kaplan D, Chiocca EA, Uchida H, Goins WF, Cohen JB, Glorioso JC, Kuppevelt TH, Mo X, Cripe TP
-
Journal Title
Gene Ther
Volume: (in press)
-
-
-
-
-
